Moleculin Biotech, Inc. 8-K

What Happened
Moleculin Biotech, Inc. announced on Feb. 19, 2026 that it entered into inducement letters with holders of certain outstanding warrants under which the holders agreed to exercise Existing Warrants to buy 2,122,652 shares at $3.90 each, providing up to approximately $8.3 million in gross proceeds. In return, the company will issue new Series H “Inducement Warrants” equal to 300% of the exercised shares (6,367,956 Inducement Warrants). The Inducement Warrants have a five‑year term and will be exercisable only after shareholder approval of the issuance of the underlying shares; the company will file a resale registration statement (S-3 or S-1) by March 31, 2026 and use commercially reasonable efforts to have it effective by April 30, 2026.

Key Details

• Existing Warrants: holders to exercise up to 2,122,652 shares at $3.90 per share, yielding up to ~$8.3M gross proceeds (before fees/expenses).
• Inducement Warrants: 6,367,956 Series H warrants (300% of exercised shares), five-year term from initial exercise date, exercisable after shareholder approval.
• Pricing & adjustments: each Inducement Warrant exercise price = lesser of $3.90 or the lowest VWAP on any trading day in the five trading days after the public announcement; subject to downward adjustments if the company issues shares at a lower price, with a floor of $0.962.
• Limitations & registration: cashless exercise allowed only if resale registration is unavailable; beneficial ownership cap of 4.99% or 9.99% (holder’s election). Roth Capital Partners was paid a 7.0% fee on gross proceeds plus $50,000 legal reimbursement. Inducement Warrants issued under a Section 4(a)(2) exemption (unregistered).

Why It Matters
This is a capital‑raising transaction that could provide Moleculin with up to ~$8.3M in immediate gross proceeds, but it also creates potential future dilution: the Inducement Warrants represent up to roughly three times the number of shares purchased now (6.37M warrants). The timing and availability of a resale registration statement (targeted filing by March 31, 2026 and effectiveness by April 30, 2026) will affect whether holders can sell shares received on exercise for cash or must use cashless exercise mechanics. Investors should note the fee to Roth Capital reduces net proceeds and the anti‑dilution and beneficial‑ownership limits that govern future exercises.